vascular arterial disease

First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA CLARA, Calif., Oct. 26, 2024 /PRNewswire/ -- Advanced NanoTherapies (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through innovative applications of nanotechnology, announced positive results from its first-in-human (FIH) trial evaluating the next-generation SirPlux™ Duo Drug-Coated Balloon (DCB). The Company also announced plans to proceed towards executing its U.S. early feasibility study (EFS), known as DYNAMIC DUO I, to evaluate the safety and performance of the SirPlux™ Duo DCB in de novo coronary lesions. SirPlux™ Duo DCB delivers a synergistic dual-drug therapy of sirolimus and paclitaxel and is engineered for vessel patency and restenosis prevention. Continue Reading SirPlux™ Duo Drug-Coated Balloon (DCB) "The innovative drug delivery platform of the SirPlux Duo DCB is poised to redefine how coronary disease is treated," stated Dr. Bernardo Cortese, MD, FESC, FSCAI, Director, Interventional Coronary Center, University Hospitals and Professor of Medicine, Case Western Reserve. "By combining two proven drugs with the novel nanoparticle technology, SirPlux Duo DCB aims to minimize drug flaking, deliver sustained drug therapy at therapeutic levels, and get the best characteristics of the two drugs, theoretically making it a strong front-line device alternative to current DCBs or drug-eluting stents." SirPlux Duo DCB is the only therapy designed to deliver sirolimus and paclitaxel simultaneously to inhibit cell growth at a higher potency and efficient dose. ANT's novel nanoparticle drug encapsulation and delivery platform is designed to provide the two drugs with safe, reliable, and sustained long-term in-tissue bioavailability with no stent burden. "We are thrilled to take this next step in further validating the clinical performance of SirPlux™ Duo DCB, a novel technology licensed from the Cleveland Clinic," said Marwan Berrada-Sounni, Co-founder and CEO of ANT. "Moving forward with our DYNAMIC DUO I EFS aligns with our vision of advancing nanotechnology-driven solutions that combine the power of sirolimus and paclitaxel to offer a safe and prolonged therapy without leaving a permanent implant behind." The planned DYNAMIC DUO I EFS study is a prospective, multi-center, non-randomized study that will enroll and treat symptomatic stable angina, unstable angina, or NSTEMI patients with de novo coronary lesions with reference vessel diameters of 2 to 4 mm. The results from this study will inform the Company on how to advance its clinical programs to broader commercialization plans in the U.S. and global markets. About Advanced NanoTherapies (ANT) Advanced NanoTherapies, Inc., a member of the T45 Labs portfolio, is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery. The Company focuses on minimally invasive cardiovascular applications to bring a safer therapeutic option to patients with arterial disease. The company's first product is the SirPlux Duo Drug-Coated Balloon (DCB), a next-generation front-line therapy for minimally invasive catheter interventions. To learn more about Advanced NanoTherapies, visit : Products are currently in development and are not available for sale. SOURCE Advanced NanoTherapies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Vesalio Introduces pVasc™ U.S. clinical study initiative to capture real-world data and optimize results for patients suffering from peripheral vascular disease PLANO, Texas, Oct. 25, 2024 /PRNewswire/ -- Vesalio, a global thrombectomy company dedicated to advancing patient care across all vascular diseases, announces the initiation of a prospective, single-arm, multi-center study supporting the recently launched pVasc™ Thrombectomy System for non-surgically removing peripheral occlusions. This multidisciplinary clinical research initiative aims to collect real-world insights on the pVasc System in treating patients suffering from peripheral arterial occlusions (PAD) that may lead to acute limb ischemia (ALI). Continue Reading pVasc Thrombectomy System Current thrombectomy tools encounter multiple challenges, including difficulty accessing smaller arteries, prolonged time to flow restoration, and the risk of distal embolization. The pVasc system, featuring next generation Drop Zone™ technology and a unique, low-profile design, is specifically engineered to address these limitations. The pVasc study will generate vital real-world evidence to support the optimization of revascularization techniques and outcomes for patients with PAD-related conditions such as ALI. Vesalio will be attending the TCT Conference (Washington, D.C., Oct. 27-30), VIVA (Las Vegas, Nov. 3-6), and VEITH Symposium (New York, Nov. 19-23) in the coming weeks. These events provide Vesalio the opportunity to connect with leading vascular experts to discuss the pVasc™ Thrombectomy System for the treatment of PAD as well as the corresponding data collection plan. "The recent launch of pVasc in the U.S. represents a major milestone in our commitment to innovating to improve patient outcomes in vascular occlusion," said Steve Rybka, CEO of Vesalio. "We expect the post-market collection of real-world data to further validate the capabilities of our technology in addressing the challenges of peripheral vascular disease. We continue to support physicians with both technology and data to achieve the best possible outcomes for their patients." About Vesalio Founded in 2017, Vesalio is a privately held medical device company focused on advancing patient care in vascular diseases by providing physicians with superior technology for improving clinical outcomes. Vesalio's proprietary NeVa™, enVast™, and pVasc™ platforms are designed to effectively remove all types of clots, leading to the revitalization of compromised ischemic tissue in the brain, heart, and peripheral anatomy. Vesalio's products have treated more than 12,000 patients in over 50 countries. For more information, visit . SOURCE Vesalio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Renowned Interventional Cardiologist Brings Expertise in Complex Coronary Artery Disease and Endovascular MedicineBOCA RATON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MyCardiologist, South Florida's trusted leader in advanced cardiovascular care, is thrilled to announce the addition of Dr. Linda Koshy to their valued medical team. Dr. Koshy, a highly skilled general and interventional cardiologist, brings specialized expertise in managing complex coronary artery disease and endovascular medicine, further enhancing the exceptional care provided by MyCardiologist. With board certifications in Interventional Cardiology, General Cardiology, Echocardiography, Nuclear Cardiology, and Vascular Interpretation, Dr. Koshy’s comprehensive background allows her to treat a wide range of cardiovascular conditions. Her procedural skills include cardiac catheterization and coronary interventions via radial approach, as well as management of arterial and venous diseases through advanced techniques like atherectomy, stenting, and endovenous ablations. Dr. Koshy will offer the full spectrum of cardiovascular care, from prevention to managing heart failure and coronary artery disease. “We are super excited to welcome Dr. Linda Koshy to our team at MyCardiologist,” said Dr. Harry Aldrich, President at MyCardiologist. “Her exceptional skill set, coupled with her passion for patient-centered care, makes her a tremendous asset to our practice and to the South Florida community.” Dr. Koshy’s impressive academic journey began at the University of Miami’s Miller School of Medicine, where she completed both her undergraduate and medical degrees through the prestigious Honors Program in Medicine. She pursued her Internal Medicine residency at Duke University Hospital and continued her training in Cardiology and Interventional Cardiology at New York University Langone Medical Center. After practicing in a multi-specialty practice in New York, she has returned to her home state of Florida to provide advanced cardiovascular care. In addition to her clinical expertise, Dr. Koshy is a strong advocate for women’s cardiovascular health and advancing the role of women in cardiology. Her interests in patient safety, quality improvement, and innovative research make her a valuable addition to the MyCardiologist team. “I am truly excited to join MyCardiologist and to bring my experience in interventional and endovascular cardiology to the South Florida community,” said Dr. Linda Koshy. “I am committed to providing patients with the highest level of care, ensuring they feel informed, comfortable, and confident in their treatment plans.” Dr. Koshy is now seeing patients at MyCardiologist’s Boca Raton location, where she offers next-day availability for appointments. Her dedication to personalized care ensures that every patient receives the attention and comprehensive care they deserve. For more information or to schedule an appointment with Dr. Linda Koshy, please contact: Boca Raton1599 NW 9th AveSuite #203Boca Raton, FL 33486Tel: 561-338-8884info@mycardiologist.com About MyCardiologist:MyCardiologist is a leading provider of cardiovascular care in South Florida, committed to excellence, wellness, and prevention. With a focus on delivering comprehensive cardiac services, the practice offers innovative diagnostic testing, treatments, and personalized patient care. MyCardiologist’s team of highly trained physicians is dedicated to improving heart health through cutting-edge technology and compassionate care. To learn more, visit www.mycardiologist.com. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9dadf658-67ec-4d99-905a-0414120b7d9f